Protocol Page


	Study ID (Protocol Number)
	CA184-240


	STUDY LOCATIONS*
	Baptist Cancer Institute Jacksonville, FL 32207 Recruiting	Dana-Farber Cancer Institute Boston, MA 02215 Recruiting
	Beverly Hills Cancer Center Beverly Hills, CA 90211 Recruiting	Dana-Farber Cancer Institute Boston, MA 02215 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
	STUDY OVERVIEW
	The purpose of this study is to determine whether the sequence of 6 wk vemurafenib followed by ipilimumab monotherapy has an acceptable safety profile with regards to the skin

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.